Clinical Study
Renal Function and NODM in De Novo Renal Transplant Recipients Treated with Standard and Reduced Levels of Tacrolimus in Combination with EC-MPS
Table 3
Adverse events (AEs) occurring in ≥20% of patients in any group, or those AEs of particular interest.
| | Events | Low-dose Tac group
(Group A), ()
n (%) | Standard-dose Tac group
(Group B), ()
n (%) |
| | Any serious adverse event | 73 (48.3) | 67 (47.5) | | Any infection | 90 (59.6) | 89 (63.1) | | Bacterial | 59 (39.1) | 65 (46.1) | | Viral | 33 (21.9) | 27 (19.1) | | Any adverse event | 145 (96.0) | 138 (97.9) | | Diarrhea | 61 (40.4) | 61 (43.3) | | Nausea | 47 (31.1) | 47 (33.3) | | Constipation | 47 (31.1) | 46 (32.6) | | Urinary tract infection | 43 (28.5) | 44 (31.2) | | Anemia | 38 (25.2) | 46 (32.6) | | Procedural pain | 31 (20.5) | 33 (23.4) | | Edema peripheral | 34 (22.5) | 25 (17.7) | | Insomnia | 21 (13.9) | 32 (22.7) | | Tremor | 18 (11.9) | 29 (20.6)1 |
|
|
1 compared to Group A.
|
